Share price · IVA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when IVA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 2 Nov 2026+4.9%
Nothing announced by IVA that day or the session before.
- 21 Oct 2026+8.9%
Nothing announced by IVA that day or the session before.
- 9 Oct 2026-4.8%
Nothing announced by IVA that day or the session before.
- 30 Sep 2026+12.2%
Nothing announced by IVA that day or the session before.
- 29 Sep 2026-6.8%
- 7 Jul 2026+16.9%
- Day beforeInventiva: 6-K filing
- 24 Jun 2026-6.7%
Nothing announced by IVA that day or the session before.
- 2 Jun 2026-14.3%
- 29 May 2026-5.7%
Nothing announced by IVA that day or the session before.
- 11 May 2026+8.0%
Nothing announced by IVA that day or the session before.
Share of unusual movement by asset
For each asset, the share of IVA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Lanifibranorevents and moves
| 3 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 18% |
| Sessions with no dated event | — | 82% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Peroxisome proliferator-activated receptors (PPARs) · PPAR (pan-agonist)Small molecule | Type 2 DiabetesMASH / NASH |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $10.0M | $98M | $100M | $50M-$93M operating cash flow | report ↗ |
View 3 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2023-FY | $19M | $119M | $30M+ <$0.1M short-term inv. | $30M-$88M operating cash flow | report ↗ |
| 2022-FY | $13M | $64M | $92M+ $1.1M short-term inv. | $14M-$47M operating cash flow | report ↗ |
| 2021-FY | $5.0M | $57M | $98M+ $10.0M short-term inv. | $15M-$56M operating cash flow | report ↗ |
Insider transactions
This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 66 reporting institutions held 52.4M shares ($290.1M, 27.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | SAMSARA BIOCAPITAL, LLC | 5,194,805 | $28.8M |
| 2 | Caligan Partners LP | 4,974,906 | $27.6M |
| 3 | Paradigm Biocapital Advisors LP | 4,000,000 | $22.2M |
| 4 | MILLENNIUM MANAGEMENT LLC | 2,987,613 | $16.6M |
| 5 | Trails Edge Capital Partners, LP | 2,657,997 | $14.8M |
| 6 | FRANKLIN RESOURCES INC | 2,461,565 | $13.7M |
| 7 | SymBiosis Capital Partners, LLC | 2,354,000 | $13.1M |
| 8 | UBS Group AG | 2,318,693 | $12.9M |
| 9 | ADAR1 Capital Management, LLC | 2,174,398 | $12.1M |
| 10 | Polar Capital Holdings Plc | 2,132,138 | $11.8M |
| 11 | ANDERA PARTNERS | 1,818,181 | $10.1M |
| 12 | Yu Fan | 1,500,000 | $8.3M |
| 13 | BOOTHBAY FUND MANAGEMENT, LLC | 1,470,407 | $8.2M |
| 14 | NEA Management Company, LLC | 1,462,586 | $8.0M |
| 15 | Ikarian Capital, LLC | 1,429,101 | $7.8M |